MedTech Industry Dynamics
MedTech Industry Dynamics
Abbott has launched its next-generation Oncodetect molecular residual disease (MRD) test, a personalized, tumor-informed whole-genome sequencing test powered by MAESTRO technology that tracks up to 5,000 patient-specific variants with a limit of detection below one part per million.
Read MoreAbbott has received CE Mark under the EU In Vitro Diagnostic Medical Devices Regulation for its Cologuard Plus stool-based DNA screening test, which detected 95% of colorectal cancers at 94% specificity in the pivotal BLUE-C study, marking a step toward bringing the noninvasive test to European markets.
Read MoreAbbott has presented new real-world evidence showing Cologuard screening was associated with 54% lower colorectal cancer incidence and 45% lower odds of death after diagnosis, while launching a new awareness campaign featuring baseball stars Albert Pujols and Cal Raleigh to encourage screening among adults 45 and older.
Read MoreJapan’s Ministry of Health, Labour and Welfare has approved Novocure’s Optune Pax for adult patients with unresectable locally advanced pancreatic cancer, used alongside gemcitabine and nab-paclitaxel, following positive results from the Phase 3 PANOVA-3 trial.
Read MoreAbbott has launched SimpleScreen CRC in the U.S., an FDA-approved blood-based colorectal cancer screening test for adults 45 and older at average risk, joining Cologuard Plus to offer healthcare providers both stool- and blood-based screening options with patient support.
Read MoreDermaSensor has commercially launched in Germany through a distribution agreement with ContraCare GmbH, marking its first European commercial launch following Class IIb CE Mark under EU MDR and a collaboration with the NHS in the United Kingdom.
Read MoreGuardant Health’s Shield blood test for colorectal cancer screening will be covered in EviCore by Evernorth clinical guidelines effective January 1, 2027, expanding commercial coverage to approximately 94 million covered lives across more than 23 states.
Read MoreMedian Technologies has signed a global strategic commercial agreement with Olea Medical, a Canon Medical Systems subsidiary, to support commercialization of its AI-powered eyonis LCS software for lung cancer screening across the United States, Europe, and other markets.
Read MoreTibaRay has announced that its first Galactica cancer treatment systems have entered manufacturing, marking a major milestone as the Stanford-founded company moves its next-generation radiotherapy technology toward clinical deployment.
Read MoreGE HealthCare and Mayo Clinic have launched the MI-BET research collaboration, a theranostics study exploring imaging- and biomarker-informed approaches to personalize radioligand therapy for patients with advanced prostate cancer.
Read More
